Congenital Myotonic Dystrophy
8
5
5
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
0.0%
0 terminated out of 8 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (8)
Trial Readiness and Endpoint Assessment in Pediatric Myotonic Dystrophy Extension
DMCRN-02-001: Assessing Pediatric Endpoints in DM1
Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry
Efficacy and Safety of Tideglusib in Congenital Myotonic Dystrophy
Tideglusib: Expanded Access Use in Congenital Myotonic Dystrophy
Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy
Trial Readiness and Endpoint Assessment in Congenital Myotonic Dystrophy
Myotonic Dystrophy Family Registry